FDA Generics Office Hopes To Begin Increasing Staff By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
To aid in ANDA assignments, OGD is developing a program to prioritize submissions as the agency addresses a 3,000-application backlog, OGD Deputy Director Robert West says during regulatory affairs specialists’ gathering in Seattle.
You may also be interested in...
China SFDA Generics Report Acknowledges Industry And Regulator Have A Long Road Ahead
A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.